Aiosyn

Aiosyn develops AI-powered software solutions for computational pathology, focusing on cancer and chronic kidney diseases. They integrate deep-learning algorithms into existing pathology workflows to enhance diagnostic accuracy, streamline operations, and accelerate drug development for clinical laboratories, research organizations, and biopharma companies. Their offerings include automated quality control for digital histology slides (AiosynQC), AI-assisted mitotic figure counting for breast cancer (Aiosyn Mitosis Breast), and precise quantification of kidney lesion scores via their NephroPath platform. Aiosyn aims to empower pathologists and support biopharma companies with data-driven insights to improve patient outcomes.